Fiduciary Trust’s Krystal Biotech KRYS Stock Holding History

Fiduciary Trust’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$217K	Hold	840	–	–	﹤0.01%	829
2025 Q4	$207K	Buy	+840	New	+$177K	﹤0.01%	834

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fiduciary Trust's KRYS Position: Q1 2026 in Review

Fiduciary Trust held its Krystal Biotech (KRYS) position steady in Q1 2026 at 840 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #829.

Fiduciary Trust first reported a position in KRYS in Q4 2025 and has held it in 2 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

Fiduciary Trust held 840 shares of Krystal Biotech worth $217K as of Q1 2026.
Fiduciary Trust left its Krystal Biotech share count unchanged in Q1 2026.
Krystal Biotech made up ﹤0.01% of Fiduciary Trust's portfolio in Q1 2026, its #829 holding.
Fiduciary Trust first reported a position in Krystal Biotech in Q4 2025 and has held it in 2 quarters since.
367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Fiduciary Trust's 13F filing for Q1 2026, filed 15 May 2026.